Iranian Journal of Nuclear Medicine

Iranian Journal of Nuclear Medicine

Production of the state of the art therapeutic radiopharmaceuticals in Iran, from beta- to alpha-emitting targeted radionuclide therapy: Clinical advances and perspectives

Document Type : Letter to the Editor

Authors
Esmail Jafari 1
Majid Assadi 1
Mohammad Eftekhari 2
1 The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran
2 Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
10.22034/irjnm.2023.129500.1595
Abstract
No abstract is available
 
Keywords
Alpha emitters
Radiopharmaceutical
Targeted therapy
Iran
Subjects
  1. Jalilian AR, Beiki D, Hassanzadeh-Rad A, Eftekhari A, Geramifar P, Eftekhari M. Production and clinical applications of radiopharmaceuticals and medical radioisotopes in Iran. Semin Nucl Med. 2016 Jul;46(4):340-58.
  2. Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020 Mar;21(3):e146-56.
  3. Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, Shafiei B, Ayati N, Amoui M. The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA. Iran J Nucl Med. 2018;26(1):2-8.
  4. Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016 Dec;57(12):1941-4.
  5. Ballal S, Yadav MP, Tripathi M, Sahoo RK, Bal C. Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and Capecitabine: A real-world scenario management based long-term outcome study. J Nucl Med. 2022 Jul 21:jnumed.122.264043.
  6. Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the most promising radionuclides for targeted alpha therapy: the "Hopeful Eight". Pharmaceutics. 2021 Jun 18;13(6):906.
  7. McDevitt MR, Sgouros G, Sofou S. Targeted and nontargeted α-particle therapies. Annu Rev Biomed Eng. 2018 Jun 4;20:73-93.
  8. Johnson JD, Heines M, Bruchertseifer F, Chevallay E, Cocolios TE, Dockx K, Duchemin C, Heinitz S, Heinke R, Hurier S, Lambert L, Leenders B, Skliarova H, Stora T, Wojtaczka W. Resonant laser ionization and mass separation of 225Ac. Sci Rep. 2023 Jan 24;13(1):1347.
  9. Ahenkorah S, Cassells I, Deroose CM, Cardinaels T, Burgoyne AR, Bormans G, Ooms M, Cleeren F. Bismuth-213 for targeted radionuclide therapy: from atom to bedside. Pharmaceutics. 2021 Apr 21;13(5):599.
  10. Vermeulen K, Vandamme M, Bormans G, Cleeren F. Design and challenges of radiopharmaceuticals. Semin Nucl Med. 2019 Sep;49(5):339-56.
  11. Jalloul W, Ghizdovat V, Stolniceanu CR, Ionescu T, Grierosu IC, Pavaleanu I, Moscalu M, Stefanescu C. Targeted alpha therapy: all we need to know about 225Ac’s physical characteristics and production as a potential theranostic radionuclide. Pharmaceutics. 2023; 16(12):1679.
  12. Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11(3):200-8.
  13. Engle JW. The production of Ac-225. Curr Radiopharm. 2018;11(3):173-179.
  14. Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011 Oct;4(4):306-20.
  15. Assadi M, Nemati R, Shooli H, Rekabpour SJ, Nabipour I, Jafari E, Gholamrezanezhad A, Amini A, Ahmadzadehfar H. An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):1015-6.
  16. Assadi M, Pirayesh E, Rekabpour SJ, Zohrabi F, Jafari E, Nabipour I, Esmaili A, Amini A, Ahmadzadehfar H. 177Lu-PSMA and 177Lu-DOTATATE Therapy in a patient with metastatic castration-resistant prostate cancer and neuroendocrine differentiation. Clin Nucl Med. 2019 Dec;44(12):978-80.
  17. Assadi M, Rekabpour SJ, Amini A, Dadgar H, Nemati R, Gholamrezanezhad A, Nabipour I, Jafari E, Ahmadzadehfar H. Peptide receptor radionuclide therapy with 177Lu-DOTATATE in a case of concurrent neuroendocrine tumors and meningioma: achieving two things in a single action. Mol Imaging Radionucl Ther. 2021 Jun 3;30(2):107-9.
  18. Dadgar H, Jafari E, Ahmadzadehfar H, Rekabpour SJ, Ravanbod MR, Kalantarhormozi M, Nabipour I, Assadi M. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma. Ann Endocrinol (Paris). 2023 Feb;84(1):45-51.
  19. Fathpour G, Jafari E, Hashemi A, Dadgar H, Shahriari M, Zareifar S, Jenabzade AR, Vali R, Ahmadzadehfar H, Assadi M. Feasibility and therapeutic potential of combined peptide receptor radionuclide therapy with intensive chemotherapy for pediatric patients with relapsed or refractory metastatic neuroblastoma. Clin Nucl Med. 2021 Jul 1;46(7):540-8.
  20. Jafari E, Ahmadzadehfar H, Bagheri D, Amini A, Assadi M. Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C. Nucl Med Commun. 2021 Mar 1;42(3):325-31.
  21. Jafari E, Amini AL, Ahmadzadehfar H, Bagheri D, Assadi M. Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors. Nuklearmedizin. 2021 Apr;60(2):99-105.
  22. Kalantarhormozi M, Hassanzadeh S, Rekabpour SJ, Ravanbod MR, Jafari E, Amini A, Dadgar H, Mahmoudpour M, Nabipour I, Jokar N, Assadi M. Peptide receptor radionuclide therapy using 177 Lu-DOTATATE in advanced neuroendocrine tumors (NETs) in a limited-resource environment. World J Nucl Med. 2022 Aug 16;21(3):215-21.
  23. Nemati R, Shooli H, Rekabpour SJ, Ahmadzadehfar H, Jafari E, Ravanbod MR, Amini A, Nemati A, Ghasemi M, Keshmiri S, Dadgar H, Assadi M. Feasibility and therapeutic potential of peptide receptor radionuclide therapy for high-grade gliomas. Clin Nucl Med. 2021 May 1;46(5):389-95.
  24. Assadi M, Rezaei S, Jafari E, Rekabpour SJ, Ravanbod MR, Zohrabi F, Amini A, Keshmiri S, Dadgar H, Ahmadzadehfar H. Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. World J Nucl Med. 2020 Feb 27;19(1):15-20.
  25. Jafari E, Ahmadzadehfar H, Dadgar H, Assadi M. An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay. World J Nucl Med. 2020 Jul 22;19(3):260-5.
  26. Ballal S, Yadav MP, Damle NA, Sahoo RK, Bal C. Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study. Clin Nucl Med. 2017 Nov;42(11):e457-66.
  27. Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):934-46.
  28. Busslinger SD, Tschan VJ, Richard OK, Talip Z, Schibli R, Müller C. [225Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [225Ac]Ac-PSMA-617. Cancers. 2022; 14(22):5651.
  29. King AP, Gutsche NT, Raju N, Fayn S, Baidoo KE, Bell MM, Olkowski CS, Swenson RE, Lin FI, Sadowski SM, Adler SS, Thiele NA, Wilson JJ, Choyke PL, Escorcia FE. 225Ac-MACROPATATE: a novel α-particle peptide receptor radionuclide therapy for neuroendocrine tumors. J Nucl Med. 2023 Apr;64(4):549-54.
  30. Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel FL, Van de Wiele C, Morgenstern A. predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020 Jan;61(1):62-9.
  31. Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017 Oct;58(10):1624-1631
  32. Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. The future of radioligand therapy: α, β, or both? J Nucl Med. 2017 Jul;58(7):1017-8.
  33. Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, Sahoo RK, Bal C. Long-term survival outcomes of salvage [225Ac] Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3777-89.
  34. Ma J, Li L, Liao T, Gong W, Zhang C. Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022 Feb 3;12:796657.
  35. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23.
  36. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014 Jun;15(7):738-46.
  37. Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester HJ, Maina T, Rösch F, van der Meulen NP, Müller C, Mäcke H, Baum RP. From bench to bedside-The Bad Berka experience with first-in-human studies. Semin Nucl Med. 2019 Sep;49(5):422-37.
  38. Serencsits B, Chu BP, Pandit-Taskar N, McDevitt MR, Dauer LT. Radiation safety considerations and clinical advantages of α-emitting therapy radionuclides. J Nucl Med Technol. 2022 Mar;50(1):10-6.
  39. Basri NA, Hashim S, Ramli AT, Bradley DA, Hamzah K. Regulatory requirements for nuclear power plant site selection in Malaysia-a review. J Radiol Prot. 2016 Dec;36(4):R96-R111.
  40. Craig AJ, Taprogge J, Flux GD, Murray I. Radiation protection aspects for alpha therapies. Q J Nucl Med Mol Imaging. 2023 Mar;67(1):4-13.